Cure My Disease

Don't miss your cure!

 Log in / Sign up

Personalized coaching may boost glaucoma treatment adherence

NCT ID NCT07793474

Disease control Sponsor: St. Joseph's Healthcare Hamilton Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This trial tests a support program for adults with glaucoma who struggle to take their eye drops regularly or attend clinic visits. Participants identify their main barrier, such as forgetfulness or difficulty using drops, and receive matching help like education, reminders, or transportation assistance. Researchers will track changes in medication adherence and appointment attendance over 12 months to see if the program improves treatment consistency and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A multi-interventional support program including education, reminders, help with eye drop technique, and assistance with transportation to appointments.
What this could lead to
If it works, this program could offer a practical way to help glaucoma patients stay on their treatment, potentially slowing vision loss and improving quality of life.
What could go wrong
The trial is relatively small and the support is tailored to individual challenges, so results may not apply to all glaucoma patients. Also, the program's success depends on patient engagement and follow-through.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 189 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Participants will be eligible for inclusion if they meet all of the following criteria: * Adults aged 18 years and older * Clinical diagnosis of glaucoma or ocular hypertension confirmed by an ophthalmologist * Currently prescribed at least one topical intraocular pressure (IOP)-lowering medication * Identified as high risk for non-adherence and/or poor follow-up, defined by one or more of the following: * Self-reported or documented missed ≥20% of prescribed eye drops * Missed two or more glaucoma clinic appointments * Evidence of structural or functional glaucoma progression (e.g., OCT or visual field deterioration) * Willing to participate in study interventions and follow-up assessments Able to communicate in the study language. Exclusion Criteria Participants will be excluded if they meet any of the following criteria: * Significant cognitive impairment, neurodegenerative disease, or severe psychiatric illness limiting participation or understanding of the intervention * Participation in another interventional study targeting glaucoma adherence or follow-up * Anticipated inability to complete 12-month follow-up (e.g., planned relocation or transfer of care outside the study catchment area)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma medication adherence are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glaucoma Medication Adherence ocular hypertension Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma medication adherence Glaucoma patients

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • St Joseph's Regional Eye Clinic

    Hamilton, Ontario, L8G 5E4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.